Achillion Pharma is also an acquisition candidate in the HCV space - Maxim
Maxim Group believes Merck (MRK) is interested in the company's nucleotide programs as well as their NS5A inhibitor. They believe that ACHN is also an acquisition candidate in the HCV space with viable NS5A, Protease Inhibitors and Nucleosides in development. As they trade today, they see Achillion as a compelling valuation.